Impax, Alexion and Depomed all have their own problems to worry about, and they're all counting on the new CEOs they just tapped to turn the situation around.
Michel Vounatsos becomes Biogen’s pick as new CEO, Gilead poaches Novartis vet Riva to head its heme/onc team, Lilly leadership shake-up sees ex-Novartis vet Shaw in and Conterno up, ex-Novartis exec David Epstein joins VC Flagship as partner, and Impax CEO Wilkinson walks out. Plus more hirings, firings and retirings throughout the industry.
